Join the Oncology Voice Network. Join for Free
Breaking Barriers in Cancer Care: Expanding Access, Innovation & Integrative Medicine
City of Hope Academic Research integrative oncology patient access

Breaking Barriers in Cancer Care: Expanding Access, Innovation & Integrative Medicine


Share This Article



Summary

Dr. Ed Kim shares insights on why redefining the standard of care is critical for improving patient outcomes, the future of clinical trials, and the role of integrative medicine in oncology.

In this episode of On the Edge of Breakthrough: Voices of Cancer Research, Dr. Monty Pal speaks with Edward S. Kim, M.D., M.B.A., the physician-in-chief of City of Hope Orange County and Vice Physician-in-Chief of City of Hope National Medical Center.  

Dr. Kim shares his experience leading the transformation of leading U.S. cancer centers, and how City of Hope is using integrative oncology to reshape the patient experience. They discuss how innovative strategies, such as building a national clinical trial model, will expand patient access and the importance of continually redefining the standard of care - not only for therapeutic solutions but also for prevention and detection interventions. Dr. Kim also opens up about mentorship and his vision for the future of cancer care.

This episode is a must-listen for anyone interested in the next frontier of oncology and what it takes to bring breakthrough treatments to more people.

Click for Source

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
What it Takes to Close the Gap in Pediatric Cancer Care with Leo Wang, M.D., Ph.D.
Partner Avatar Monty Pal

What it Takes to Close the Gap in Pediatric Cancer Care with Leo Wang, M.D., Ph.D.

Podcast
Reengineering CAR T for Solid Tumors: What Glioblastoma Has Taught Us with Christine Brown, Ph.D.
Partner Avatar Monty Pal

Reengineering CAR T for Solid Tumors: What Glioblastoma Has Taught Us with Christine Brown, Ph.D.

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Article
Outcome measures for oncology alternative payment models: practical considerations and recommendations
OVN Avatar Jakub P. Hlávka, PhD, Pei-Jung Lin, PhD, Peter J. Neumann, ScD

Outcome measures for oncology alternative payment models: practical considerations and recommendations

Article
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
OVN Avatar Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Explore OVN